Irish Prostate Cancer Outcomes Research (IPCOR) registry: cohort profile

PurposeTo describe the Irish Prostate Cancer Outcomes Research (IPCOR) registry. The cohort was collected to inform and improve the prostate cancer journey of men in Ireland.ParticipantsEstablished in 2015, IPCOR was a unique large-scale prospective cohort study registering men with prostate cancer...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2024-12, Vol.14 (12), p.e090207
Main Authors: Gordon, Noa, Dooley, Cara, Murphy, Áine, Farooq, Wasfa, Sullivan, Frank, McDermott, Ray, Sharp, Linda, Watson, William, Galvin, David
Format: Article
Language:English
Subjects:
Aged
Cancer therapies
Clinical outcomes
Cohort Profile
Hospitals
Humans
Ireland
Ireland - epidemiology
Male
Middle Aged
Oncology
Outcome Assessment, Health Care
Patient Reported Outcome Measures
Patients
Population
Prospective Studies
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - therapy
Radiation
REGISTRIES
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PurposeTo describe the Irish Prostate Cancer Outcomes Research (IPCOR) registry. The cohort was collected to inform and improve the prostate cancer journey of men in Ireland.ParticipantsEstablished in 2015, IPCOR was a unique large-scale prospective cohort study registering men with prostate cancer in Ireland. From 2016 to 2020, IPCOR collected data on 6816 men who were newly diagnosed with prostate cancer across 16 hospitals, both public and private. A comprehensive clinical dataset was collected, capturing detailed information on men’s diagnosis, treatments and follow-up. In addition, a subset of 873 men completed patient-reported outcome measures.Findings to dateThe IPCOR study has revealed several key insights into prostate cancer diagnosis and treatment in Ireland. The data indicate a high rate of diagnosis through opportunistic Prostate-Specific Antigen screening, with many cases identified at an early stage.Future plansIPCOR invites collaboration from the global cancer research community to use this resource to advance prostate cancer research and improve patient outcomes worldwide. IPCOR aims to continue updating long-term survival follow-up data for this cohort. It also plans to continue its collaborative approach with patients, engaging with the Lived Experience Advisory Panel in interpreting results emerging from this dataset. Moving forward, IPCOR is planning its next phase of the project, IPCOR 2.0. This will be a prospective, longitudinal, multi-centre clinical quality registry and biorepository.
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2024-090207